US FDA Review Teams Face ‘Herculean’ Shift to Two-Month Timelines With New Voucher

 
• By Sue Sutter
  
CBER's Katherine Szarama (left) chats with ASGCT Chief Advocacy Officer Margarita Valdez Martinez. (Sue Sutter)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies